Tipanat 20 Tablet (20’s) is a specialized medication that combines two active ingredients, Tipiracil (8.19 mg) and Trifluridine (20 mg), to effectively treat certain types of cancer, particularly metastatic colorectal cancer. This combination works synergistically to inhibit tumor growth and proliferation, making it a vital option in cancer therapy. Tipiracil acts as a thymidine phosphorylase inhibitor, enhancing the bioavailability of Trifluridine, which is an antimetabolite that interferes with DNA synthesis in cancer cells. By disrupting the replication process, Tipanat 20 Tablet helps to slow down or stop the growth of cancerous cells, providing a crucial treatment avenue for patients battling this disease. The formulation is designed for oral administration, making it convenient for patients to incorporate into their treatment regimen. Overall, Tipanat 20 Tablet represents a significant advancement in cancer treatment, offering hope to those affected by aggressive forms of the disease.